UBS AG London Branch Warrant on WuXi Biologics (Cayman) Inc. (58219)
Market Closed
HKEX HKEX Primary - Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
HKD
Previous Close Want to track 58219 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
58219 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
58219 Chart
UBS AG London Branch Warrant on WuXi Biologics (Cayman) Inc. (58219) FAQ
What is the stock price today?
The current price is 0.00 HKD.
On which exchange is it traded?
UBS AG London Branch Warrant on WuXi Biologics (Cayman) Inc. is listed on HKEX.
What is its stock symbol?
The ticker symbol is 58219.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has UBS AG London Branch Warrant on WuXi Biologics (Cayman) Inc. ever had a stock split?
No, there has never been a stock split.
UBS AG London Branch Warrant on WuXi Biologics (Cayman) Inc. Profile
| Financial Services Industry | Financials Sector | - CEO | HKEX Exchange | - ISIN |
| Hong Kong Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
UBS AG London Branch Warrant on WuXi Biologics (Cayman) Inc. is a structured derivative product issued by UBS that provides leveraged exposure to WuXi Biologics, a leading global contract development and manufacturing organization (CDMO) specializing in biologics. This warrant allows investors to gain indirect exposure to WuXi Biologics' end-to-end solutions for drug discovery, development, and manufacturing across multiple markets including China, North America, Europe, and Asia-Pacific regions. WuXi Biologics operates through its Biologics and XDC segments, offering comprehensive services from concept through commercial manufacturing using proprietary platforms such as WuXiBody and SDArBodY. The warrant provides a way for investors to participate in the growth of the biologics manufacturing sector with enhanced price movement relative to the underlying stock, making it suitable for investors seeking amplified exposure to this specialized pharmaceutical services provider. The product is structured for Hong Kong market investors and carries the associated risks and benefits of warrant instruments.
Contact Information
Address: -
Phone: -
